DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition.

Saved in:
Bibliographic Details
Title: DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition.
Authors: Ayyadevara VSSA; Department of Basic Science, Division of Cancer Sciences, Loma Linda University School of Medicine, Loma Linda, CA, USA., Wertheim G; Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Gaur S; Department of Basic Science, Division of Cancer Sciences, Loma Linda University School of Medicine, Loma Linda, CA, USA., Chukinas JA; Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Loftus JP; Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Lee SJ; Department of Systems Biology, City of Hope Beckman Research Institute, Duarte, CA, USA., Kumar A; Department of Systems Biology, City of Hope Beckman Research Institute, Duarte, CA, USA., Swaminathan S; Department of Systems Biology, City of Hope Beckman Research Institute, Duarte, CA, USA.; Department of Pediatrics, City of Hope Beckman Research Institute, Duarte, CA, USA., Bhansali RS; Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Childers W; Moulder Center for Drug Discovery, Temple University School of Pharmacy, Philadelphia, PA, USA., Geng H; Department of Laboratory Medicine, University of California, San Francisco, CA, USA., Milne TA; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK., Hua X; Department of Cancer Biology, Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Bernt KM; Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.; Department of Pediatrics and Abramson Cancer Center at the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Besson T; Univ Rouen Normandie, INSA Rouen Normandie, CNRS, Institut CARMeN UMR 6064, Rouen, France., Shi J; Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Crispino JD; Division of Experimental Hematology, St Jude Children's Research Hospital, Memphis, TN, USA., Carroll M; Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Tasian SK; Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA. tasians@chop.edu.; Department of Pediatrics and Abramson Cancer Center at the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. tasians@chop.edu.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. tasians@chop.edu., Hurtz C; Department of Basic Science, Division of Cancer Sciences, Loma Linda University School of Medicine, Loma Linda, CA, USA. Churtz@LLU.edu.
Source: Leukemia [Leukemia] 2025 May; Vol. 39 (5), pp. 1078-1089. Date of Electronic Publication: 2025 Mar 27.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5551
DOI:10.1038/s41375-025-02575-w